{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:05:12Z","timestamp":1787166312090,"version":"build-2736575974"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2017,12,6]],"date-time":"2017-12-06T00:00:00Z","timestamp":1512518400000},"content-version":"vor","delay-in-days":5,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["AG056931"],"award-info":[{"award-number":["AG056931"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s13195-017-0327-x","type":"journal-article","created":{"date-parts":[[2017,12,6]],"date-time":"2017-12-06T06:53:42Z","timestamp":1512543222000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Study partners should be required in preclinical Alzheimer\u2019s disease trials"],"prefix":"10.1186","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4215-7589","authenticated-orcid":false,"given":"Joshua D.","family":"Grill","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Karlawish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,12,6]]},"reference":[{"key":"327_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jalz.2016.07.150","volume":"13","author":"A Wimo","year":"2017","unstructured":"Wimo A, Guerchet M, Ali GC, et al. The worldwide costs of dementia 2015 and comparisons with 2010. Alzheimers Dement. 2017;13:1\u20137.","journal-title":"Alzheimers Dement."},{"key":"327_CR2","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","volume":"7","author":"RA Sperling","year":"2011","unstructured":"Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:280\u201392.","journal-title":"Alzheimers Dement."},{"key":"327_CR3","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.jalz.2016.02.002","volume":"12","author":"B Dubois","year":"2016","unstructured":"Dubois B, Hampel H, Feldman HH, et al. Preclinical Alzheimer's disease: definition, natural history, and diagnostic criteria. Alzheimers Dement. 2016;12:292\u2013323.","journal-title":"Alzheimers Dement."},{"key":"327_CR4","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1212\/WNL.0b013e318232ac1a","volume":"77","author":"J Karlawish","year":"2011","unstructured":"Karlawish J. Addressing the ethical, policy, and social challenges of preclinical Alzheimer disease. Neurology. 2011;77:1487\u201393.","journal-title":"Neurology."},{"key":"327_CR5","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1212\/WNL.0000000000000153","volume":"82","author":"JJ Arias","year":"2014","unstructured":"Arias JJ, Karlawish J. Confidentiality in preclinical Alzheimer disease studies: when research and medical records meet. Neurology. 2014;82:725\u20139.","journal-title":"Neurology."},{"key":"327_CR6","doi-asserted-by":"publisher","first-page":"9","DOI":"10.2217\/nmt.12.75","volume":"3","author":"JD Grill","year":"2013","unstructured":"Grill JD, Johnson DK, Burns JM. Should we disclose amyloid imaging results to cognitively normal individuals? Neurodegener Dis Manag. 2013;3:9.","journal-title":"Neurodegener Dis Manag."},{"key":"327_CR7","doi-asserted-by":"publisher","first-page":"219","DOI":"10.2217\/nmt.13.25","volume":"3","author":"JS Roberts","year":"2013","unstructured":"Roberts JS, Dunn LB, Rabinovici GD. Amyloid imaging, risk disclosure and Alzheimer's disease: ethical and practical issues. Neurodegener Dis Manag. 2013;3:219\u201329.","journal-title":"Neurodegener Dis Manag."},{"key":"327_CR8","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1212\/WNL.56.6.789","volume":"56","author":"JH Karlawish","year":"2001","unstructured":"Karlawish JH, Casarett D, Klocinski J, Sankar P. How do AD patients and their caregivers decide whether to enroll in a clinical trial? Neurology. 2001;56:789\u201392.","journal-title":"Neurology."},{"key":"327_CR9","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1097\/JGP.0b013e318162992d","volume":"16","author":"J Karlawish","year":"2008","unstructured":"Karlawish J, Kim SY, Knopman D, van Dyck CH, James BD, Marson D. The views of Alzheimer disease patients and their study partners on proxy consent for clinical trial enrollment. Am J Geriatr Psychiatr. 2008;16:240\u20137.","journal-title":"Am J Geriatr Psychiatr."},{"key":"327_CR10","volume-title":"Study partners perform essential tasks in dementia research and can experience burdens and benefits in this role","author":"BS Black","year":"2016","unstructured":"Black BS, Taylor HA, Rabins PV, Karlawish J. Study partners perform essential tasks in dementia research and can experience burdens and benefits in this role. London: Dementia; 2016."},{"key":"327_CR11","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.jalz.2006.04.003","volume":"2","author":"RC Mohs","year":"2006","unstructured":"Mohs RC, Kawas C, Carrillo MC. Optimal design of clinical trials for drugs designed to slow the course of Alzheimer's disease. Alzheimers Dement. 2006;2:131\u20139.","journal-title":"Alzheimers Dement."},{"key":"327_CR12","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.neurobiolaging.2015.11.007","volume":"39","author":"JD Grill","year":"2016","unstructured":"Grill JD, Zhou Y, Elashoff D, Karlawish J. Disclosure of amyloid status is not a barrier to recruitment in preclinical Alzheimer's disease clinical trials. Neurobiol Aging. 2016;39:147\u201353.","journal-title":"Neurobiol Aging."},{"key":"327_CR13","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1001\/jamaneurol.2014.803","volume":"71","author":"MC Donohue","year":"2014","unstructured":"Donohue MC, Sperling RA, Salmon DP, et al. The preclinical Alzheimer cognitive composite: measuring amyloid-related decline. JAMA Neurol. 2014;71:961\u201370.","journal-title":"JAMA Neurol."},{"key":"327_CR14","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.jalz.2014.02.002","volume":"10","author":"JB Langbaum","year":"2014","unstructured":"Langbaum JB, Hendrix SB, Ayutyanont N, et al. An empirically derived composite cognitive test score with improved power to track and evaluate treatments for preclinical Alzheimer's disease. Alzheimers Dement. 2014;10:666\u201374.","journal-title":"Alzheimers Dement."},{"key":"327_CR15","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1212\/WNL.0b013e31826e26db","volume":"79","author":"JM Burns","year":"2012","unstructured":"Burns JM, Klunk WE. Predicting positivity for a new era of Alzheimer disease prevention trials. Neurology. 2012;79:1530\u20131.","journal-title":"Neurology."},{"issue":"14","key":"327_CR16","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1212\/WNL.0000000000001451","volume":"84","author":"SY Kim","year":"2015","unstructured":"Kim SY, Karlawish J, Berkman BE. Ethics of genetic and biomarker test disclosures in neurodegenerative disease prevention trials. Neurology. 2015;84(14):1488\u201394.","journal-title":"Neurology"},{"key":"327_CR17","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s13195-015-0112-7","volume":"7","author":"K Harkins","year":"2015","unstructured":"Harkins K, Sankar P, Sperling R, et al. Development of a process to disclose amyloid imaging results to cognitively normal older adult research participants. Alzheimers Res Ther. 2015;7:26.","journal-title":"Alzheimers Res Ther."},{"key":"327_CR18","doi-asserted-by":"publisher","first-page":"e1002254","DOI":"10.1371\/journal.pmed.1002254","volume":"14","author":"J Qian","year":"2017","unstructured":"Qian J, Wolters FJ, Beiser A, et al. APOE-related risk of mild cognitive impairment and dementia for prevention trials: an analysis of four cohorts. PLoS Med. 2017;14:e1002254.","journal-title":"PLoS Med."},{"issue":"4","key":"327_CR19","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.jalz.2015.09.005","volume":"12","author":"YY Lim","year":"2016","unstructured":"Lim YY, Maruff P, Getter C, Snyder PJ. Disclosure of positron emission tomography amyloid imaging results: a preliminary study of safety and tolerability. Alzheimers Dement. 2016;12(4):454\u20138.","journal-title":"Alzheimers Dement"},{"issue":"9","key":"327_CR20","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1016\/j.jalz.2017.01.022","volume":"13","author":"JM Burns","year":"2017","unstructured":"Burns JM, Johnson DK, Liebmann EP, Bothwell RJ, Morris JK, Vidoni ED. Safety of disclosing amyloid status in cognitively normal older adults. Alzheimers Dement. 2017;13(9):1024\u201330.","journal-title":"Alzheimers Dement"},{"key":"327_CR21","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1056\/NEJMoa0809578","volume":"361","author":"RC Green","year":"2009","unstructured":"Green RC, Roberts JS, Cupples LA, et al. Disclosure of APOE genotype for risk of Alzheimer's disease. N Engl J Med. 2009;361:245\u201354.","journal-title":"N Engl J Med."},{"key":"327_CR22","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1038\/ejhg.2010.119","volume":"18","author":"S Ashida","year":"2010","unstructured":"Ashida S, Koehly LM, Roberts JS, Chen CA, Hiraki S, Green RC. The role of disease perceptions and results sharing in psychological adaptation after genetic susceptibility testing: the REVEAL Study. Eur J Hum Genet. 2010;18:1296\u2013301.","journal-title":"Eur J Hum Genet."},{"key":"327_CR23","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1080\/10810730903295518","volume":"14","author":"S Ashida","year":"2009","unstructured":"Ashida S, Koehly LM, Roberts JS, Chen CA, Hiraki S, Green RC. Disclosing the disclosure: factors associated with communicating the results of genetic susceptibility testing for Alzheimer's disease. J Health Commun. 2009;14:768\u201384.","journal-title":"J Health Commun."},{"issue":"3","key":"327_CR24","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1097\/WAD.0000000000000097","volume":"29","author":"RJ Caselli","year":"2015","unstructured":"Caselli RJ, Marchant GE, Hunt KS, et al. Predictive testing for Alzheimer's disease: suicidal ideation in healthy participants. Alzheimer Dis Assoc Disord. 2015;29(3):252\u20134.","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"327_CR25","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.trci.2015.12.001","volume":"2","author":"BR Ott","year":"2016","unstructured":"Ott BR, Pelosi MA, Tremont G, Snyder PJ. A survey of knowledge and views concerning genetic and amyloid PET status disclosure. Alzheimers Dement (N Y). 2016;2:23\u20139.","journal-title":"Alzheimers Dement (N Y)"},{"key":"327_CR26","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/j.mayocp.2014.05.016","volume":"89","author":"RJ Caselli","year":"2014","unstructured":"Caselli RJ, Langbaum J, Marchant GE, et al. Public perceptions of presymptomatic testing for Alzheimer disease. Mayo Clin Proc. 2014;89:1389\u201396.","journal-title":"Mayo Clin Proc."},{"key":"327_CR27","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1212\/WNL.48.6.1508","volume":"48","author":"JC Morris","year":"1997","unstructured":"Morris JC, Ernesto C, Schafer K, et al. Clinical dementia rating training and reliability in multicenter studies: the Alzheimer's Disease Cooperative Study experience. Neurology. 1997;48:1508\u201310.","journal-title":"Neurology."},{"key":"327_CR28","doi-asserted-by":"publisher","first-page":"S109","DOI":"10.1097\/01.wad.0000213870.40300.21","volume":"20","author":"SH Ferris","year":"2006","unstructured":"Ferris SH, Aisen PS, Cummings J, et al. ADCS Prevention Instrument Project: overview and initial results. Alzheimer Dis Assoc Disord. 2006;20:S109\u201323.","journal-title":"Alzheimer Dis Assoc Disord."},{"key":"327_CR29","doi-asserted-by":"publisher","first-page":"S152","DOI":"10.1097\/01.wad.0000213873.25053.2b","volume":"20","author":"D Galasko","year":"2006","unstructured":"Galasko D, Bennett DA, Sano M, Marson D, Kaye J, Edland SD. ADCS Prevention Instrument Project: assessment of instrumental activities of daily living for community-dwelling elderly individuals in dementia prevention clinical trials. Alzheimer Dis Assoc Disord. 2006;20:S152\u201369.","journal-title":"Alzheimer Dis Assoc Disord."},{"key":"327_CR30","doi-asserted-by":"crossref","unstructured":"Sperling RA, Rentz DM, Johnson KA, et al. The A4 study: stopping AD before symptoms begin? Sci Transl Med. 2014;6:228fs213.","DOI":"10.1126\/scitranslmed.3007941"},{"key":"327_CR31","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1212\/WNL.58.5.758","volume":"58","author":"MH Tabert","year":"2002","unstructured":"Tabert MH, Albert SM, Borukhova-Milov L, et al. Functional deficits in patients with mild cognitive impairment: prediction of AD. Neurology. 2002;58:758\u201364.","journal-title":"Neurology."},{"key":"327_CR32","doi-asserted-by":"publisher","first-page":"S170","DOI":"10.1097\/01.wad.0000213879.55547.57","volume":"20","author":"SP Walsh","year":"2006","unstructured":"Walsh SP, Raman R, Jones KB, Aisen PS. ADCS Prevention Instrument Project: the Mail-In Cognitive Function Screening Instrument (MCFSI). Alzheimer Dis Assoc Disord. 2006;20:S170\u20138.","journal-title":"Alzheimer Dis Assoc Disord."},{"issue":"4","key":"327_CR33","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1001\/jamaneurol.2014.3375","volume":"72","author":"RE Amariglio","year":"2015","unstructured":"Amariglio RE, Donohue MC, Marshall GA, et al. Tracking early decline in cognitive function in older individuals at risk for Alzheimer disease dementia: the Alzheimer's Disease Cooperative Study Cognitive Function Instrument. JAMA Neurol. 2015;72(4):446\u201354.","journal-title":"JAMA Neurol"},{"key":"327_CR34","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.jalz.2013.02.007","volume":"10","author":"KA Gifford","year":"2014","unstructured":"Gifford KA, Liu D, Lu Z, et al. The source of cognitive complaints predicts diagnostic conversion differentially among nondemented older adults. Alzheimers Dement. 2014;10:319\u201327.","journal-title":"Alzheimers Dement."},{"key":"327_CR35","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1016\/j.jalz.2007.10.007","volume":"4","author":"CL Meinert","year":"2008","unstructured":"Meinert CL, Breitner JC. Chronic disease long-term drug prevention trials: lessons from the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT). Alzheimers Dement. 2008;4:S7\u2013S14.","journal-title":"Alzheimers Dement."},{"key":"327_CR36","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1212\/WNL.0b013e31827debfe","volume":"80","author":"JD Grill","year":"2013","unstructured":"Grill JD, Raman R, Ernstrom K, Aisen P, Karlawish J. Effect of study partner on the conduct of Alzheimer disease clinical trials. Neurology. 2013;80:282\u20138.","journal-title":"Neurology."},{"key":"327_CR37","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1097\/WAD.0b013e3181c9983f","volume":"24","author":"SD Edland","year":"2010","unstructured":"Edland SD, Emond JA, Aisen PS, Petersen RC. NIA-funded Alzheimer centers are more efficient than commercial clinical recruitment sites for conducting secondary prevention trials of dementia. Alzheimer Dis Assoc Disord. 2010;24:159\u201364.","journal-title":"Alzheimer Dis Assoc Disord."},{"key":"327_CR38","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1097\/WNN.0b013e318190cf75","volume":"21","author":"DS Knopman","year":"2008","unstructured":"Knopman DS. Clinical trial design issues in mild to moderate Alzheimer disease. Cogn Behav Neurol. 2008;21:197\u2013201.","journal-title":"Cogn Behav Neurol."},{"key":"327_CR39","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1212\/WNL.55.11.1724","volume":"55","author":"DB Carr","year":"2000","unstructured":"Carr DB, Gray S, Baty J, Morris JC. The value of informant versus individual's complaints of memory impairment in early dementia. Neurology. 2000;55:1724\u20136.","journal-title":"Neurology."},{"issue":"13","key":"327_CR40","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1056\/NEJMp1302513","volume":"368","author":"N Kozauer","year":"2013","unstructured":"Kozauer N, Katz R. Regulatory innovation and drug development for early-stage Alzheimer's disease. N Engl J Med. 2013;368(13):1169\u201371.","journal-title":"N Engl J Med"},{"key":"327_CR41","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1097\/WAD.0000000000000048","volume":"29","author":"CM Callahan","year":"2015","unstructured":"Callahan CM, Tu W, Stump TE, Clark DO, Unroe KT, Hendrie HC. Errors in self-reports of health services use: impact on Alzheimer disease clinical trial designs. Alzheimer Dis Assoc Disord. 2015;29:75\u201381.","journal-title":"Alzheimer Dis Assoc Disord."},{"issue":"12","key":"327_CR42","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1001\/jamainternmed.2016.6310","volume":"176","author":"J Karlawish","year":"2016","unstructured":"Karlawish J, Langa KM. Unfinished business in preventing Alzheimer disease. JAMA Int Med. 2016;176(12):1739\u201340.","journal-title":"JAMA Int Med"},{"key":"327_CR43","volume-title":"Telling the Truth in Diagnosis","author":"Alzheimer's Association","year":"2011","unstructured":"Alzheimer's Association. Telling the Truth in Diagnosis. 2011. http:\/\/www.alz.org\/professionals_and_researchers_diagnostic_disclosure.asp , Accessed 31 Mar 2014."},{"key":"327_CR44","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s13195-016-0223-9","volume":"8","author":"M Sheffrin","year":"2016","unstructured":"Sheffrin M, Stijacic Cenzer I, Steinman MA. Desire for predictive testing for Alzheimer's disease and impact on advance care planning: a cross-sectional study. Alzheimers Res Ther. 2016;8:55.","journal-title":"Alzheimers Res Ther."},{"key":"327_CR45","doi-asserted-by":"crossref","unstructured":"Ott BR, Jones RN, Noto RB, et al. Brain amyloid in preclinical Alzheimer's disease is associated with increased driving risk. Alzheimers Dement (Amst). 2017;6:136\u201342.","DOI":"10.1016\/j.dadm.2016.10.008"},{"key":"327_CR46","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1001\/jama.2011.187","volume":"305","author":"CP Sabatino","year":"2011","unstructured":"Sabatino CP. Damage prevention and control for financial incapacity. JAMA. 2011;305:707\u20138.","journal-title":"JAMA."},{"key":"327_CR47","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1097\/00002093-200401000-00003","volume":"18","author":"RE Ready","year":"2004","unstructured":"Ready RE, Ott BR, Grace J. Validity of informant reports about AD and MCI patients' memory. Alzheimer Dis Assoc Disord. 2004;18:11\u20136.","journal-title":"Alzheimer Dis Assoc Disord."},{"key":"327_CR48","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1159\/000272423","volume":"29","author":"JL Conde-Sala","year":"2010","unstructured":"Conde-Sala JL, Garre-Olmo J, Turro-Garriga O, Vilalta-Franch J, Lopez-Pousa S. Quality of life of patients with Alzheimer's disease: differential perceptions between spouse and adult child caregivers. Dement Geriatr Cogn Disord. 2010;29:97\u2013108.","journal-title":"Dement Geriatr Cogn Disord."},{"key":"327_CR49","unstructured":"National Academies of Sciences, Engineering, and Medicine. Families caring for an aging America. Washington, DC; 2016. https:\/\/www.nap.edu\/catalog\/23606\/families-caring-for-an-aging-america ."},{"key":"327_CR50","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1212\/WNL.0000000000001364","volume":"84","author":"RB Postuma","year":"2015","unstructured":"Postuma RB, Gagnon JF, Bertrand JA, Genier Marchand D, Montplaisir JY. Parkinson risk in idiopathic REM sleep behavior disorder: preparing for neuroprotective trials. Neurology. 2015;84:1104\u201313.","journal-title":"Neurology."}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-017-0327-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13195-017-0327-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-017-0327-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,23]],"date-time":"2020-10-23T18:18:07Z","timestamp":1603477087000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-017-0327-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["327"],"URL":"https:\/\/doi.org\/10.1186\/s13195-017-0327-x","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"6 December 2017","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Joshua Grill, PhD, has served as an investigator on studies sponsored by Eli Lilly & Company, Biogen Idec, and the Alzheimer\u2019s Disease Cooperative Study.Jason Karlawish, MD, is a co-holder of a license of an Integrated NeuroDegenerative Disease Database developed at the University of Pennsylvania. He receives royalties for \"Do We Have a Pill for That: Treating Dementia\", Johns Hopkins University Press.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 information"}},{"value":"This study does not meet the criteria for human subject research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"93"}}